Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Allos Therapeutics, Inc. (“Allos” or the “Company”) (NASDAQ: ALTH) concerning AMAG Pharmaceuticals, Inc.’s (“AMAG”) (NASDAQ: AMAG) offer to buy the Company in an all-stock deal that values the Company at approximately $285 million. Under the terms of the proposed transaction, Allos shareholders will receive a fixed ratio of 0.1282 shares of AMAG common stock for each share of Allos common stock they own, valuing Allos stock at $2.44 a share based on yesterday’s closing price of AMAG shares.

Our investigation concerns whether the board of directors is undertaking a fair process to obtain fair consideration for all shareholders of Allos.

If you own shares of Allos and would like to learn more about these claims or if you wish to discuss this matter and have any questions or information concerning this announcement, please contact Robert I. Harwood, Esq. at rharwood@hfesq.com or Peter W. Overs, Jr., Esq. at povers@hfesq.com. You may also call them at (877) 935-7400. For more information about class actions, or to sign up online, please visit our website: www.hfesq.com.

Harwood Feffer LLP is a national shareholder litigation firm. Harwood Feffer LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

Attorney Advertising. © 2011 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.